
Conference Coverage
Latest Content

Exploratory Study of Selected Stakeholder Insights Into Continuous Glucose Monitoring in T2D With Risk-Sharing Agreements

GLP-1 Receptor Agonists: Trend, Necessity, or Blessing?

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML

'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum

EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Updated results highlight the promise of epcoritamab combined with chemotherapy for newly diagnosed DLBCL.

A panel at the American Society of Hematology highlights the urgent need for genetic diversity in cancer studies, addressing disparities in treatment outcomes across different ancestries.

Families of children with acute lymphoblastic leukemia face significant financial toxicity, with many experiencing severe economic hardship during treatment.

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Rusfertide shows promise in maintaining hematocrit control and improving quality of life for polycythemia vera patients, reducing phlebotomy needs significantly.

Experts at an Institute for Value-Based Medicine event held October 14, 2025, in Aurora, Colorado, explored advances in neurology care, cross-specialty collaboration, and strategies to improve access and therapy.

Quality improvement programs markedly increase sleep apnea testing in stroke patients, showing effective ways to improve guideline-based care.

Public health dental hygienists expand dental care access and oral health education in underserved communities, improving overall health outcomes.


























































